{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:37:38Z","timestamp":1790696258507,"version":"4.1.0"},"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>While establishing worldwide collective immunity with anti SARS-CoV-2 vaccines, COVID-19 remains a major health issue with dramatic ensuing economic consequences. In the transition, repurposing existing drugs remains the fastest cost-effective approach to alleviate the burden on health services, most particularly by reducing the incidence of the acute respiratory distress syndrome associated with severe COVID-19. We undertook a computational repurposing approach to identify candidate therapeutic drugs to control progression towards severe airways inflammation during COVID-19. Molecular profiling data were obtained from public sources regarding SARS-CoV-2 infected epithelial or endothelial cells, immune dysregulations associated with severe COVID-19 and lung inflammation induced by other respiratory viruses. From these data, we generated a protein-protein interactome modeling the evolution of lung inflammation during COVID-19 from inception to an established cytokine release syndrome. This predictive model assembling severe COVID-19-related proteins supports a role for known contributors to the cytokine storm such as IL1\u03b2, IL6, TNF\u03b1, JAK2, but also less prominent actors such as IL17, IL23 and C5a. Importantly our analysis points out to alarmins such as TSLP, IL33, members of the S100 family and their receptors (ST2, RAGE) as targets of major therapeutic interest. By evaluating the network-based distances between severe COVID-19-related proteins and known drug targets, network computing identified drugs which could be repurposed to prevent or slow down progression towards severe airways inflammation. This analysis confirmed the interest of dexamethasone, JAK2 inhibitors, estrogens and further identified various drugs either available or in development interacting with the aforementioned targets. We most particularly recommend considering various inhibitors of alarmins or their receptors, currently receiving little attention in this indication, as candidate treatments for severe COVID-19.<\/jats:p>","DOI":"10.1371\/journal.pone.0254374","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T17:50:21Z","timestamp":1626976221000},"page":"e0254374","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19"],"prefix":"10.1371","volume":"16","author":[{"given":"Emiko","family":"Desvaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che\u00efma","family":"Boudjeniba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Chassagnol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Swindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-6223","authenticated-orcid":true,"given":"Audrey","family":"Aussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Laigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Laplume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Soret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Jean-Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Dupin-Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-957X","authenticated-orcid":true,"given":"Micka\u00ebl","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-9983","authenticated-orcid":true,"given":"Philippe","family":"Moingeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"pone.0254374.ref001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/d41586-021-00031-0","article-title":"Could new COVID variants undermine vaccines? Labs scramble to find out","volume":"589","author":"E Callaway","year":"2021","journal-title":"Nature"},{"key":"pone.0254374.ref002","unstructured":"Group TRC. Dexamethasone in Hospitalized Patients with Covid-19\u2014Preliminary Report. New England Journal of Medicine. 2020 [cited 18 Jan 2021]."},{"key":"pone.0254374.ref003","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"JH Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0254374.ref004","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial","volume":"181","author":"C Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"pone.0254374.ref005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial","volume":"181","author":"O Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"pone.0254374.ref006","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19\u2014Interim WHO Solidarity Trial Results","volume":"384","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"pone.0254374.ref007","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"F Krammer","year":"2020","journal-title":"Nature"},{"key":"pone.0254374.ref008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Y Zhou","year":"2020","journal-title":"Cell Discov"},{"key":"pone.0254374.ref009","author":"S Nabirotchkin","year":"2020","journal-title":"Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19"},{"key":"pone.0254374.ref010","author":"X Li","year":"2020","journal-title":"Network Bioinformatics Analysis Provides Insight into Drug Repurposing for COVID-2019"},{"key":"pone.0254374.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.04.005","article-title":"Boosting the arsenal against COVID-19 through computational drug repurposing","volume":"25","author":"G Ciliberto","year":"2020","journal-title":"Drug Discovery Today"},{"key":"pone.0254374.ref012","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/biology10010002","article-title":"Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease","volume":"10","author":"KH Chowdhury","year":"2021","journal-title":"Biology"},{"key":"pone.0254374.ref013","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"J Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pone.0254374.ref014","article-title":"Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19","author":"DM Gysi","year":"2020","journal-title":"arXiv:200407229 [cs, q-bio, stat]"},{"key":"pone.0254374.ref015","doi-asserted-by":"crossref","first-page":"e1008686","DOI":"10.1371\/journal.pcbi.1008686","article-title":"SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19","volume":"17","author":"G Fiscon","year":"2021","journal-title":"PLOS Computational Biology"},{"key":"pone.0254374.ref016","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12859-021-04076-w","article-title":"SAveRUNNER: An R-based tool for drug repurposing","volume":"22","author":"G Fiscon","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"pone.0254374.ref017","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s13054-020-03240-7","article-title":"Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey","volume":"24","author":"SJ Tzotzos","year":"2020","journal-title":"Critical Care"},{"key":"pone.0254374.ref018","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200678","article-title":"The many faces of the anti-COVID immune response","volume":"217","author":"SA Vardhana","year":"2020","journal-title":"J Exp Med"},{"key":"pone.0254374.ref019","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"JB Moore","year":"2020","journal-title":"Science"},{"key":"pone.0254374.ref020","volume":"11","author":"R de la Rica","year":"2020","journal-title":"COVID-19: In the Eye of the Cytokine Storm. Front Immunol"},{"key":"pone.0254374.ref021","doi-asserted-by":"crossref","first-page":"10331","DOI":"10.1038\/ncomms10331","article-title":"Network-based in silico drug efficacy screening","volume":"7","author":"E Guney","year":"2016","journal-title":"Nature Communications"},{"key":"pone.0254374.ref022","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-018-05116-5","article-title":"Network-based approach to prediction and population-based validation of in silico drug repurposing","volume":"9","author":"F Cheng","year":"2018","journal-title":"Nat Commun"},{"key":"pone.0254374.ref023","article-title":"SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems","author":"D Blanco-Melo","year":"2020","journal-title":"bioRxiv"},{"key":"pone.0254374.ref024","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19","volume":"383","author":"M Ackermann","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"pone.0254374.ref025","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"M Liao","year":"2020","journal-title":"Nature Medicine"},{"key":"pone.0254374.ref026","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"AG Laing","year":"2020","journal-title":"Nature Medicine"},{"key":"pone.0254374.ref027","article-title":"Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients","author":"J Hadjadj","year":"2020","journal-title":"medRxiv"},{"key":"pone.0254374.ref028","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2334-4-34","article-title":"A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection","volume":"4","author":"LFP Ng","year":"2004","journal-title":"BMC Infect Dis"},{"key":"pone.0254374.ref029","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","article-title":"Immune determinants of COVID-19 disease presentation and severity","volume":"27","author":"P Brodin","year":"2021","journal-title":"Nature Medicine"},{"key":"pone.0254374.ref030","first-page":"1","article-title":"Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discovery","volume":"6","author":"W Wen","year":"2020"},{"key":"pone.0254374.ref031","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12931-020-01511-z","article-title":"Inflammatory phenotyping predicts clinical outcome in COVID-19","volume":"21","author":"H Burke","year":"2020","journal-title":"Respiratory Research"},{"key":"pone.0254374.ref032","doi-asserted-by":"crossref","first-page":"28336","DOI":"10.1073\/pnas.2018030117","article-title":"Transcriptional and proteomic insights into the host response in fatal COVID-19 cases","volume":"117","author":"M Wu","year":"2020","journal-title":"PNAS"},{"key":"pone.0254374.ref033","first-page":"1","article-title":"Global absence and targeting of protective immune states in severe COVID-19","author":"AJ Combes","year":"2021","journal-title":"Nature"},{"key":"pone.0254374.ref034","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"PS Arunachalam","year":"2020","journal-title":"Science"},{"key":"pone.0254374.ref035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"M Merad","year":"2020","journal-title":"Nature Reviews Immunology"},{"key":"pone.0254374.ref036","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: Current State of the Science","volume":"52","author":"N Vabret","year":"2020","journal-title":"Immunity"},{"key":"pone.0254374.ref037","article-title":"Clinical and immunological factors that distinguish COVID-19 from pandemic influenza A(H1N1)","author":"JA Chore\u00f1o-Parra","year":"2020","journal-title":"medRxiv"},{"key":"pone.0254374.ref038","doi-asserted-by":"crossref","DOI":"10.3410\/B5-3","article-title":"Cytokines in chronic respiratory diseases","volume":"5","author":"SP Atamas","year":"2013","journal-title":"F1000 Biol Rep"},{"key":"pone.0254374.ref039","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000904","article-title":"A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study","volume":"4","author":"M Wang","year":"2021","journal-title":"Life Science Alliance"},{"key":"pone.0254374.ref040","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.545089","article-title":"Designing a Network Proximity-Based Drug Repurposing Strategy for COVID-19","volume":"8","author":"P Stolfi","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"pone.0254374.ref041","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrg.2017.38","article-title":"Network propagation: a universal amplifier of genetic associations","volume":"18","author":"L Cowen","year":"2017","journal-title":"Nature Reviews Genetics"},{"key":"pone.0254374.ref042","doi-asserted-by":"crossref","first-page":"11087","DOI":"10.1096\/fj.202001062R","article-title":"Network determinants of cardiovascular calcification and repositioned drug treatments","volume":"34","author":"J-S Song","year":"2020","journal-title":"FASEB J"},{"key":"pone.0254374.ref043","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/nar\/30.1.412","article-title":"TTD: Therapeutic Target Database","volume":"30","author":"X Chen","year":"2002","journal-title":"Nucleic acids research"},{"key":"pone.0254374.ref044","doi-asserted-by":"crossref","first-page":"D901","DOI":"10.1093\/nar\/gkm958","article-title":"DrugBank: a knowledgebase for drugs, drug actions and drug targets","volume":"36","author":"DS Wishart","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"pone.0254374.ref045","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41467-019-09186-x","article-title":"Network-based prediction of drug combinations","volume":"10","author":"F Cheng","year":"2019","journal-title":"Nature Communications"},{"key":"pone.0254374.ref046","doi-asserted-by":"crossref","first-page":"e76339","DOI":"10.1371\/journal.pone.0076339","article-title":"Going the Distance for Protein Function Prediction: A New Distance Metric for Protein Interaction Networks","volume":"8","author":"M Cao","year":"2013","journal-title":"PLOS ONE"},{"key":"pone.0254374.ref047","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"J Lamb","year":"2006","journal-title":"Science"},{"key":"pone.0254374.ref048","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.4049\/jimmunol.1901350","article-title":"A Critical Role for the CXCL3\/CXCL5\/CXCR2 Neutrophilic Chemotactic Axis in the Regulation of Type 2 Responses in a Model of Rhinoviral-Induced Asthma Exacerbation","volume":"205","author":"LA Sokulsky","year":"2020","journal-title":"The Journal of Immunology"},{"key":"pone.0254374.ref049","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the `Cytokine Storm\u2019 in COVID-19","volume":"80","author":"Q Ye","year":"2020","journal-title":"J Infect"},{"key":"pone.0254374.ref050","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"DE Leisman","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"pone.0254374.ref051","unstructured":"Information NC for B, Pike USNL of M 8600 R, MD B, Usa 20894. National Center for Biotechnology Information. [cited 19 May 2021]. https:\/\/www.ncbi.nlm.nih.gov\/"},{"key":"pone.0254374.ref052","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41577-020-0328-z","article-title":"COVID-19: a case for inhibiting IL-17?","volume":"20","author":"O Pacha","year":"2020","journal-title":"Nature reviews Immunology"},{"key":"pone.0254374.ref053","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","article-title":"Association of COVID-19 inflammation with activation of the C5a\u2013C5aR1 axis","volume":"588","author":"J Carvelli","year":"2020","journal-title":"Nature"},{"key":"pone.0254374.ref054","article-title":"A Novel Use of Romiplostim for SARS-CoV-2\u2013induced Thrombocytopenia","author":"CW Schneider","year":"2021","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"pone.0254374.ref055","article-title":"Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and death in animal models","author":"JSY Ho","year":"2020","journal-title":"bioRxiv"},{"key":"pone.0254374.ref056","first-page":"90","article-title":"The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19","volume":"1","author":"PC Robinson","year":"2020","journal-title":"Med (N Y)"},{"key":"pone.0254374.ref057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572635","article-title":"A \u201cWindow of Therapeutic Opportunity\u201d for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019","volume":"11","author":"L De Stefano","year":"2020","journal-title":"Front Immunol"},{"key":"pone.0254374.ref058","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/annrheumdis-2020-218122","article-title":"Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study","volume":"79","author":"E Della-Torre","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"pone.0254374.ref059","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis","volume":"324","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group","year":"2020","journal-title":"JAMA"},{"key":"pone.0254374.ref060","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19","volume":"41","author":"W Luo","year":"2020","journal-title":"Trends in Pharmacological Sciences"},{"key":"pone.0254374.ref061","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK Inhibition as a New Treatment Strategy for Patients with COVID-19","volume":"181","author":"F Seif","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"pone.0254374.ref062","doi-asserted-by":"crossref","first-page":"102571","DOI":"10.1016\/j.autrev.2020.102571","article-title":"Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies","volume":"19","author":"P Fagone","year":"2020","journal-title":"Autoimmunity Reviews"},{"key":"pone.0254374.ref063","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tem.2020.11.004","article-title":"Sex and COVID-19: A Protective Role for Reproductive Steroids","volume":"32","author":"G Pinna","year":"2021","journal-title":"Trends in Endocrinology & Metabolism"},{"key":"pone.0254374.ref064","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3324\/haematol.2020.260117","article-title":"Complement C5 inhibition in patients with COVID-19\u2014a promising target?","volume":"105","author":"R Peffault de Latour","year":"2020","journal-title":"Haematologica"},{"key":"pone.0254374.ref065","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100590","article-title":"Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study","volume":"28","author":"D Annane","year":"2020","journal-title":"EClinicalMedicine"},{"key":"pone.0254374.ref066","first-page":"4040","article-title":"Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience","volume":"24","author":"F Diurno","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"pone.0254374.ref067","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study","volume":"11","author":"V Giudice","year":"2020","journal-title":"Front Pharmacol"},{"key":"pone.0254374.ref068","first-page":"1","article-title":"The receptor for advanced glycation end product (RAGE) pathway in COVID-19","author":"D Yalcin Kehribar","year":"2021","journal-title":"Biomarkers"},{"key":"pone.0254374.ref069","article-title":"LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro","author":"A Roth","year":"2020","journal-title":"bioRxiv"},{"key":"pone.0254374.ref070","article-title":"Downregulation of Defensin genes in SARS-CoV-2 infection","author":"MM Idris","year":"2020","journal-title":"medRxiv"},{"key":"pone.0254374.ref071","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12577","article-title":"ALARMINS AND IMMUNITY","volume":"280","author":"D Yang","year":"2017","journal-title":"Immunol Rev"},{"key":"pone.0254374.ref072","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41423-020-0492-x","article-title":"Elevated serum levels of S100A8\/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients","volume":"17","author":"L Chen","year":"2020","journal-title":"Cellular & Molecular Immunology"},{"key":"pone.0254374.ref073","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cell.2020.08.002","article-title":"Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19","volume":"182","author":"A Silvin","year":"2020","journal-title":"Cell"},{"key":"pone.0254374.ref074","article-title":"Autoimmunity to the Lung Protective Phospholipid-Binding Protein Annexin A2 Predicts Mortality Among Hospitalized COVID-19 Patients","author":"M Zuniga","year":"2021","journal-title":"medRxiv"},{"key":"pone.0254374.ref075","doi-asserted-by":"crossref","first-page":"18665","DOI":"10.1038\/s41598-020-75618-0","article-title":"Serum S100B protein as a marker of severity in Covid-19 patients","volume":"10","author":"A Aceti","year":"2020","journal-title":"Scientific Reports"},{"key":"pone.0254374.ref076","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2217\/bmm-2020-0410","article-title":"Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19","volume":"14","author":"Z Zeng","year":"2020","journal-title":"Biomarkers in Medicine"},{"key":"pone.0254374.ref077","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1016\/S2665-9913(20)30340-4","article-title":"Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?","volume":"2","author":"G Zizzo","year":"2020","journal-title":"The Lancet Rheumatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T17:51:06Z","timestamp":1626976266000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254374"}},"subtitle":[],"editor":[{"given":"Svetlana P.","family":"Chapoval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":77,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0254374","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]}}}